Madison biopharmaceutical company Mithridion recently secured $1.25 million in funding from Venture Investors, The State of Wisconsin Investment Board, and Rocket Venture Fund. Mithridion is developing drug candidates that focus on serious Central Nervous System disorders, including Alzheimer’s disease. From their press release:
“We plan to use this new funding to explore additional niche disease targets for MCD-386CR,
our lead clinical drug candidate, which is a new strategy for the company, to seek partners for
our drug candidates MCD-386CR and MI-10-022 for Alzheimer’s disease (AD) and
schizophrenia, and to augment our science advisory board and board of directors,†said Trevor
M. Twose, Ph.D., the company’s Chief Executive. “We greatly appreciate the continued
confidence of our shareholders,†he added.